BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-901@pharmaconomics
DTSTAMP:20260707T034447Z
DTSTART;VALUE=DATE:20260326
DTEND;VALUE=DATE:20260327
SUMMARY:OCGN Phase 2 — OCU400
DESCRIPTION:Phase 2 trial results for OCU400 in Retinitis Pigmentosa are due Mar 26\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1372299/000162828026021541/corporatedeck_march26x20.htm\n\nTrack it: https://www.pharmaconomics.com/e/901
URL:https://www.pharmaconomics.com/e/901
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:OCGN catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR